Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052779 · ClinicalTrials.gov registry record · Phase 2
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
A Phase 2 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT01052779 is a Phase 2 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 162 participants.
The verdict
NCT01052779, a Phase 2 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in participants with chronic kidney disease (CKD).
Interventions
- DRUG Ferumoxytol
- DRUG Iron Sucrose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2010-03-01 |
| Est. Completion | 2012-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052779
The ClinicalTrials.gov registry entry for NCT01052779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01052779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052779 about?
NCT01052779 is a clinical study titled "A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease". The purpose of the study is to evaluate the safety and efficacy of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in participants with chronic kidney disease (CKD).
What is the current status of trial NCT01052779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2010-03-01. Estimated completion is 2012-04-19.
What interventions are being tested in trial NCT01052779?
The interventions under investigation include: Ferumoxytol (DRUG), Iron Sucrose (DRUG).
Who is sponsoring clinical trial NCT01052779?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.